# US 2025/0144029 A1 · Novel compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144029 A1
- Document ID: US20250144029A1
- Status: Published application
- Kind: A1
- Application number: 18/832,674
- Filed: 2023-01-27
- Published: 2025-05-08
- Earliest claimed: 2022-01-27
- Assignees: Intra-Cellular Therapies, Inc.
- Applicants: Intra-Cellular Therapies, Inc.
- Inventors: Peng LI
- Web page: https://patentgrep.com/patent/US20250144029A1

## CPC

- A61K 9/146: {with organic macromolecular compounds}
- A61K 9/145: {with organic compounds}
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/38: Cellulose; Derivatives thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure relates to amorphous solid dispersions comprising (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-2-((4-(6-fluoropyridin-2-yl)phenyl)methyl)-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2H)-one and an excipient, as well as related methods of making and using such dispersions.

## Claims

### Claim 1

An amorphous solid dispersion comprising (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-2-((4-(6-fluoropyridin-2-yl)phenyl)methyl)-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2H)-one (Compound 1) in free base or pharmaceutically acceptable salt form and an excipient.

### Claim 2 (depends on 1)

The amorphous solid dispersion according to claim 1, wherein Compound 1 is in free base form.

### Claim 3 (depends on 1)

The amorphous solid dispersion according to claim 1, wherein Compound 1 is in phosphate salt form.

### Claim 4 (depends on 1)

The amorphous solid dispersion according to claim 1, wherein the excipient comprises a cellulose; polyethylene glycol (e.g., polyethylene glycol having a molecular weight of 500-50000 Daltons, e.g., PEG 1000 or PEG 10000); monostearine; polyvinyl pyrrolidone; PEG/PPG block co-polymers (e.g., a poloxamer (e.g., poloxamer 407, pluronic F127)); ascorbic acid (i.e., L-ascorbic acid); butylated hydroxyanisole; sodium dodecyl sulfate; a cyclodextrin (e.g., beta cyclodextrin, 2-Hydroxy propyl)-β-cyclodextrin); or combinations thereof.

### Claim 5 (depends on 1)

The amorphous solid dispersion according to claim 1, wherein the excipient comprises cellulose; hydroxypropyl cellulose; methyl cellulose; hydroxy propyl methyl cellulose; sodium dodecyl sulfate; ascorbic acid (e.g., L-ascorbic acid); beta-cyclodextrin; (2-hydroxypropyl) beta-cyclodextrin; cellulose acetate; cellulose acetate phthalate; polyethylene glycol (e.g., polyethylene glycol having a molecular weight of 500-50000 Daltons, e.g., PEG 1000 or PEG 10000); PEG/PPG block co-polymers (e.g., a poloxamer (e.g., poloxamer 407, pluronic F127)); butylated hydroxyanisole; monostearine; or combinations thereof.

### Claim 6 (depends on 1)

The amorphous solid dispersion according to claim 1, wherein the excipient comprises cellulose, methyl cellulose; hydroxy propyl methyl cellulose; (2-hydroxypropyl) beta-cyclodextrin; cellulose acetate; cellulose acetate phthalate; polyvinyl pyrrolidone (e.g., K85-K95); ascorbic acid (e.g., L-ascorbic acid); or combinations thereof.

### Claim 7 (depends on 1)

The amorphous solid dispersion according to claim 1, wherein Compound 1 and the excipient are present in a molar ratio between 1:5 to 5:1, e.g., a molar ratio between 1:2 and 2:1, e.g., 1:1, 1:2, or 2:1.

### Claim 8 (depends on 1)

The amorphous solid dispersion according to claim 1, wherein the amorphous solid dispersion is in dosage form, which contains Compound 1 in an amount of about 0.5 mg to about 300 mg, wherein the amount is calculated as the free base equivalent.

### Claim 9 (depends on 1)

The amorphous solid dispersion according to claim 1, wherein the amorphous solid dispersion is in dosage form, which contains Compound 1 in an amount of about 30 mg to about 90 mg, wherein the amount is calculated as the free base equivalent.

### Claim 10 (depends on 1)

The amorphous solid dispersion according to claim 1, wherein the amorphous solid dispersion is stable for a period of about one day, about three days, or about 7 days under accelerated aging conditions (e.g., 40° C. and 75% relative humidity).

### Claim 11 (depends on 1)

The amorphous solid dispersion according to claim 1, wherein Compound 1 is amorphous and contains less than 10 wt. % crystalline forms of Compound 1, e.g., less than 5 wt. % crystalline forms of Compound 1, e.g., less than 1 wt. % crystalline forms of Compound 1, e.g., less than 0.1 wt. % crystalline forms of Compound 1, e.g., less than 0.01 wt. % crystalline forms of compound 1, e.g., essentially free of crystalline forms of Compound 1.

### Claim 12 (depends on 1)

A method of making an amorphous solid dispersion comprising (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-2-((4-(6-fluoropyridin-2-yl)phenyl)methyl)-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2H)-one (Compound 1) and an excipient according to claim 1, the method comprising the steps of:
a) dissolving Compound 1 in a first solvent;
b) dissolving the excipient in a second solvent;
c) combining the solutions from steps a) and b); and
d) removing the solvents from the mixture.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the first solvent comprises one or more of water, acetone, dichloromethane, an alcohol (e.g., methanol or ethanol), dioxane, tetrahydrofuran, acetonitrile, and combinations thereof.

### Claim 14 (depends on 12)

The method according to claim 12, wherein the first solvent is acetone; dichloromethane; acetone and ethanol (e.g., in a 3:1 ratio); tetrahydrofuran and water (e.g., in a 9:1 ratio); methanol and water (e.g., in a ratio of 9:1); or acetonitrile and water (e.g., in a ratio of 9:1).

### Claim 15 (depends on 12)

The method according to claim 12, wherein the second solvent is water and/or methanol.

### Claim 16 (depends on 12)

The method according to claim 12, wherein removing the solvents from the mixture comprises lyophilization and/or evaporation.

### Claim 17 (depends on 12)

The method according to claim 12, wherein the removal step comprises lyophilization and evaporation.

### Claim 18 (depends on 12)

The method according to claim 12, wherein the removal step comprises freezing the mixture at a temperature at or below 0° C., e.g., at or below −10° C., e.g., at or below −20° C., followed by evaporation of the solvent at reduced pressure (e.g., 0 bar).

### Claim 19 (depends on 12)

The method according to claim 12, wherein the removal step comprises evaporation of the solvent at reduced pressure (e.g., 0 bar).

### Claim 20 (depends on 1)

A method for the prophylaxis or treatment of a patient, e.g., a human, suffering from a disorder selected from the following:
i. Neurodegenerative diseases, including Parkinson's disease, restless leg, tremors, dyskinesias, Huntington's disease, Alzheimer's disease, and drug-induced movement disorders;
ii. Mental disorders, including depression, attention deficit disorder, attention deficit hyperactivity disorder, bipolar illness, anxiety, sleep disorders, e.g., narcolepsy, cognitive impairment, e.g., cognitive impairment of schizophrenia, dementia, Tourette's syndrome, autism, fragile X syndrome, psychostimulant withdrawal, and drug addiction;
iii. Circulatory and cardiovascular disorders, including cerebrovascular disease, stroke, congestive heart disease, hypertension, pulmonary hypertension, e.g., pulmonary arterial hypertension, and sexual dysfunction, including cardiovascular diseases and related disorders;
iv. Respiratory and inflammatory disorders, including asthma, chronic obstructive pulmonary disease, and allergic rhinitis, as well as autoimmune and inflammatory diseases;
v. Diseases that may be alleviated by the enhancement of progesterone-signaling such as female sexual dysfunction;
vi. A disease or disorder such as psychosis, glaucoma, or elevated intraocular pressure;
vii. Traumatic brain injury;
viii. Cancers or tumors, e.g., brain tumors, a glioma (e.g., ependymoma, astrocytoma, oligodendrogliomas, brain stem glioma, optic nerve glioma, or mixed gliomas, e.g., oligoastrocytomas), an astrocytoma (e.g., glioblastoma multiforme), osteosarcoma, melanoma, leukemia, neuroblastoma or leukemia;
ix. Renal disorders, e.g., kidney fibrosis, chronic kidney disease, renal failure, glomerulosclerosis and nephritis;
x. Any disease or condition characterized by low levels of cAMP and/or cGMP (or inhibition of cAMP and/or cGMP signaling pathways) in cells expressing PDE1; and/or
xi. Any disease or condition characterized by reduced dopamine D1 receptor signaling activity,
the method comprising administering to a patient in need thereof a therapeutically effective amount of an amorphous solid dispersion comprising (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-2-((4-(6-fluoropyridin-2-yl)phenyl)methyl)-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2H)-one (Compound 1) in free base or pharmaceutically acceptable salt form and an excipient according to claim 1.
